Tags: Drug.

Omacetaxine mepesuccinate (INN trade name Synribo) is a pharmaceutical drug that is indicated for treatment of chronic myelogenous leukemia (CML). It is a semi-synthetic derivative of the alkaloid cephalotaxine from Cephalotaxus harringtonia. It was approved by the US FDA in October 2012 for the treatment of adult patients with CML with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKIs).

Omacetaxine2DACS.svg
ATC prefix
L01
ATC suffix
XX40
CAS number
26833-87-4
ChEBI
71019
FDA UNII code
6FG8041S5B
IUPAC name
1-((1S3aR14bS)-2-Methoxy-1568914b-hexahydro-4H-cyclopenta(a)(13)dioxolo(45-h)pyrrolo(21-b)(3)benzazepin-1-yl) 4-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate
PubChem
285033

Loading...

This page contains content from the copyrighted Wikipedia article "Omacetaxine mepesuccinate"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.